What are the key takeaways from this The Life Science Rundown episode?

Key insights include: **Intentional Innovation Crossover:** Separate innovation teams from execution teams structurally, but create a formal gate process where leadership decides when an innovation is ready to enter the manufacturing pipeline. This prevents premature implementation while keeping scientific progress moving, and gives regulators documented evidence of deliberate, confidence-backed process changes rather than reactive decisions.; **Tiered Escalation with Rapid Response:** Build manufacturing operations around a tiered daily escalation system where frontline teams hold decision-making authority, with issues elevated only as severity warrants. Layer in a dedicated rapid response team for critical failures. In autologous cell therapy, where patient material turnaround is time-sensitive, this structure directly reduces batch loss risk.; **Talent Hiring Minimums:** Define non-negotiable baseline skills before recruiting — for example, aseptic manufacturing technique for production roles — then train modality-specific knowledge internally. This narrows candidate pools to those with transferable fundamentals while preserving training resources for cell therapy specifics, and reduces onboarding time without compromising quality or compliance standards.

What did Nelly Viseux discuss on The Life Science Rundown?

Nelly Viseux, VP of Cell Therapy Development at Puageneron, outlines how biotech leaders build resilient organizations in cell and gene therapy by embedding adaptability, empowerment, and intentional innovation into team structures, talent strategy, quality systems, and data-driven decision-making across the full development lifecycle. Key topics include: **Intentional Innovation Crossover:** Separate innovation teams from execution teams structurally, but create a formal gate process where leadership decides when an innovation is ready to enter the manufacturing pipeline. This prevents premature implementation while keeping scientific progress moving, and gives regulators documented evidence of deliberate, confidence-backed process changes rather than reactive decisions.; **Tiered Escalation with Rapid Response:** Build manufacturing operations around a tiered daily escalation system where frontline teams hold decision-making authority, with issues elevated only as severity warrants. Layer in a dedicated rapid response team for critical failures. In autologous cell therapy, where patient material turnaround is time-sensitive, this structure directly reduces batch loss risk..

How long is this episode of The Life Science Rundown?

This episode is 37 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Life Science Rundown

Building Resilient Biotech Teams in Cell and Gene Therapy with Nelly Viseux

February 9, 2026

37 min episode · 2 min read

Nelly Viseux

Episode

37 min

Read time

2 min

Topics

Career Growth, Startups, Leadership

AI-Generated Summary

Published Mar 16, 2026

Key Takeaways

✓Intentional Innovation Crossover: Separate innovation teams from execution teams structurally, but create a formal gate process where leadership decides when an innovation is ready to enter the manufacturing pipeline. This prevents premature implementation while keeping scientific progress moving, and gives regulators documented evidence of deliberate, confidence-backed process changes rather than reactive decisions.
✓Tiered Escalation with Rapid Response: Build manufacturing operations around a tiered daily escalation system where frontline teams hold decision-making authority, with issues elevated only as severity warrants. Layer in a dedicated rapid response team for critical failures. In autologous cell therapy, where patient material turnaround is time-sensitive, this structure directly reduces batch loss risk.
✓Talent Hiring Minimums: Define non-negotiable baseline skills before recruiting — for example, aseptic manufacturing technique for production roles — then train modality-specific knowledge internally. This narrows candidate pools to those with transferable fundamentals while preserving training resources for cell therapy specifics, and reduces onboarding time without compromising quality or compliance standards.
✓Cross-Lifecycle Data Mining: In autologous cell therapy, consolidate data across the full patient-to-patient product lifecycle into a shared data lake accessible to manufacturing, clinical, and scientific teams simultaneously. Each function interprets the same dataset differently, and cross-functional dashboard reviews — read-only, published regularly — surface patterns that siloed reporting would miss and inform process hypothesis testing.
✓Anticipatory Compliance Scaling: During Phase 1, actively evaluate whether current manufacturing technology — traditional CMO processes versus closed, automated, robotic systems — can meet the compliance bar expected at later development stages. Engage regulatory agencies early with comparative data showing equivalence between manual and automated outputs, rather than waiting until scale-up forces a reactive technology transition.

What It Covers

Nelly Viseux, VP of Cell Therapy Development at Puageneron, outlines how biotech leaders build resilient organizations in cell and gene therapy by embedding adaptability, empowerment, and intentional innovation into team structures, talent strategy, quality systems, and data-driven decision-making across the full development lifecycle.

Key Questions Answered

•Intentional Innovation Crossover: Separate innovation teams from execution teams structurally, but create a formal gate process where leadership decides when an innovation is ready to enter the manufacturing pipeline. This prevents premature implementation while keeping scientific progress moving, and gives regulators documented evidence of deliberate, confidence-backed process changes rather than reactive decisions.
•Tiered Escalation with Rapid Response: Build manufacturing operations around a tiered daily escalation system where frontline teams hold decision-making authority, with issues elevated only as severity warrants. Layer in a dedicated rapid response team for critical failures. In autologous cell therapy, where patient material turnaround is time-sensitive, this structure directly reduces batch loss risk.
•Talent Hiring Minimums: Define non-negotiable baseline skills before recruiting — for example, aseptic manufacturing technique for production roles — then train modality-specific knowledge internally. This narrows candidate pools to those with transferable fundamentals while preserving training resources for cell therapy specifics, and reduces onboarding time without compromising quality or compliance standards.
•Cross-Lifecycle Data Mining: In autologous cell therapy, consolidate data across the full patient-to-patient product lifecycle into a shared data lake accessible to manufacturing, clinical, and scientific teams simultaneously. Each function interprets the same dataset differently, and cross-functional dashboard reviews — read-only, published regularly — surface patterns that siloed reporting would miss and inform process hypothesis testing.
•Anticipatory Compliance Scaling: During Phase 1, actively evaluate whether current manufacturing technology — traditional CMO processes versus closed, automated, robotic systems — can meet the compliance bar expected at later development stages. Engage regulatory agencies early with comparative data showing equivalence between manual and automated outputs, rather than waiting until scale-up forces a reactive technology transition.

Notable Moment

Viseux describes how, as an analytical development scientist, she found it more unsettling when an experiment succeeded on the first attempt without a clear explanation than when it failed. That mindset now drives her organization's entire continuous improvement and root cause culture.

Know someone who'd find this useful?

Episode Transcript

Hello, everyone. Welcome to the Life Science Rundown, the podcast where we discuss current regulatory complexities facing the life science industry and explore innovative ways to overcome those challenges. I am your host, Nicholas Catman, president and CEO of the FDA Group. Before we get started, here's a quick word about who we are. The FDA Group is a consulting firm that helps life science companies in the areas of regulatory submissions, audit projects, mock inspections, staff augmentation, and remediation. So if you're a friend yourself in need, just head over to the fdagroup.com to check us out and get in touch. So today, I am speaking with Neli Bizzou. I I know. I try I try my best. I try my best. You're doing great. Neli, thank you so much for joining me today. You thank you for having me. Absolutely. So before we jump in, would you kindly introduce yourself? Yes. So, Neli, please, I'm currently working at Puageneron. I am the vice president of cell therapy development manufacturing supply and quality. I have about twenty years of experience in biotechnology, worked at large company on for about half of my career, Shire, Biogen, Baxter, then moved into a, startup world where I tackled nanoparticle. I made a switch to, cell and gene therapy, and I've been working in that field for over ten years now. So that's where I'm coming from, and I'm happy to talk from that perspective. Excellent. So today, we're gonna talk about how can leaders in the biotech industry, especially in cell and gene therapies, build resilient organizations to tackle innovation and the demands of development to bring medicines to market. So we have a lot to talk about, a lot to cover. So we're gonna jump right into it. So first, how do leaders define organizational resilience within the unique scientific regulatory and operational demands of cell and gene therapy development? Yeah. So maybe first to put some context around the question, I'm going to talk about cell therapy, cell and gene therapy. For me, they are interchangeable for this particular discussion. I will not make a a differentiation. Cell therapy in general is a it's not necessarily new. We don't have a lot of approved product yet compared to potentially other modalities, but it's a fast evolving. It's a very competitive field, and it's a biologically complex field. And so that actually MDN is in terms of the resilience of an organization. And so for me, I translate organizational resilience into adaptability. Adaptability, the capacity to absorb change and to actually anticipate those change. So in the question, we talk about regulatory changes. We need to be working with the regulatory agencies to actually get the product to patients, and that's important that we actually have that back and forth communication. For the most part, we can anticipate or at least foresee some of the changes that we will be facing. That's a little bit easier. On the operational side, changes …

Get the full transcript (6,059 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Life Science Rundown transcripts →